A randomized open-label study to compare the effects of amlodipine and cilnidipine on heart rate and proteinuria in subjects with hypertension with proteinuria

Shanbhag, Ajay D; Gowda, Hema Narasimhe; Laxmegowda,

doi:10.5455/njppp.2018.8.0723228072018

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blocking of N-type CC provides additional organ protective activity to cilnidipine, like cardio-protection and reno-protection [ 21 ]. One study among subjects with proteinuria also shows that cilnidipine is a better anti-hypertensive and reno-protective drug than amlodipine [ 22 ]. In another study conducted among diabetic hypertensives, cilnidipine shows similar BP-reducing potential as olmesartan, although both drugs act by different mechanisms; however, cilnidipine reduces micro-albuminuria more effectively than olmesartan [ 23 ].…”

Section: Reviewmentioning

confidence: 99%

Blood Pressure Reducing Potential and Renoprotective Action of Cilnidipine Among Hypertensive Patients Suffering From Chronic Kidney Disease: A Meta-Analysis

Rohilla¹,

Sinha²,

Toppo³

et al. 2023

Cureus

View full text Add to dashboard Cite

Hypertension is a risk factor for cardiovascular diseases which also causes progressive kidney damage leading to chronic kidney disease (CKD), so the rate of progression of CKD can be controlled by reducing blood pressure (BP). Many anti-hypertensive drugs are available. Cilnidipine is a new-generation calcium channel blocker (CCB). This meta-analysis is aimed to generate pooled evidence about the effectiveness of cilnidipine as an anti-hypertensive and to explore its reno-protective actions. Pubmed, Scopus, Cochrane Library, and Google Scholar were searched from January 2000 to December 2022 to include the studies. The pooled mean difference, along with 95% CI, was computed using Revman 5.4.1 software (Revman International, Inc., New York City, New York). The Cochrane risk-of-bias assessment tool was used for bias assessment. This meta-analysis was registered in PROSPERO with Reg. no. CRD42023395224. This metaanalysis included seven studies with 289 participants in the intervention group and 269 in the comparator group, and were selected from Japan, India, and Korea. Systolic blood pressure (SBP) was significantly reduced in cilnidipine treated group among hypertensives with CKD subjects weighted mean difference (WMD) was 4.33, and the 95% confidence interval (CI) was 1.26 to 7.31 as compared to the other group. Cilnidipine also shows a significant reduction in proteinuria with WMD 0.61 and 95% CI 0.42 to 0.80. Both groups were similar in adverse drug reactions (ADR). Cilnidipine is a more effective anti-hypertensive as compared to Amlodipine or other CCBs, mainly in reducing SBP. Besides this, cilnidipine also shows better reno-protective action because it also significantly reduces proteinuria in such patients.

show abstract

Section: Reviewmentioning

confidence: 99%